ArticleGalen medical journal2024
Accuracy of Prenatal Ultrasonography for Diagnosis of Placenta Accreta Spectrum and Risk Factors in A Tertiary Center in Southern Iran.
Article in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Association between Serum Biochemical Markers and Early Amniocentesis in Diagnosing Chromosomal Anomalies: A Cross-Sectional Study in Southern Iran, 2021-2022.Iranian journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlacenta accreta spectrum is one of the most important causes of massive bleeding in the peripartum period. The aim of this study was to determine the accuracy of prenatal ultrasonography for diagnosis of placenta accreta spectrum (PAS) and important risk factors of this pathology were evaluated in this report. MATERIALS AND
methodsThis is a cross-sectional study conducted at Shiraz University of Medical Sciences during January 2018 to January 2019. All patients who were referred for ultrasound examination of placenta accrete spectrum and surgery in Hafez tertiary center were included. Patients with diagnosis of PAS in pathology were in one group and the others in the second group. All maternal and neonatal and demographic data and surgery complications were gathered in a data form.
resultsUltrasonography was 100% (95% C.I: 94.40%-100%) sensitive, 87.58% (95% C.I; 81.29%-92.36) specific, and 87.58% (95% C.I: 82.44%-91.66%) accurate discriminating PAS from non-PAS patients. From 217 patients, 64 and 153 patients were in PAS and non-PAS group, respectively. There was significantly more age, gravidity, live children, history of DC, hormonal contraception, and history of previa in PAS group compared with Non-PAS group (p-value0.05 for all); however, gestational age was significantly lower in PAS group (p-value0.05). The odds of PAS significantly increase with previa and low-lying placenta OR adj (95% C.I): 114.68 (28.45-462.29). The patients with one C/S OR adj (95% C.I): 29.07(3.80-222.33) and the patients with two C/S OR adj (95% C.I): 106.08(13.79-815.51) were significantly more in PAS group compared with those with no C/S (p-value 0.05 for both).
conclusionDetection rate of ultrasound examination was good, and it is recommended for women with PAS risk factors. Decreasing the rate of cesarean section and encouraging vaginal birth after cesarean section (VBAC) are the best ways of prevention of this pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.